4
Clinical Trials associated with Asparaginase (Pharmedic Laboratories Pvt Ltd.)A single-arm prospective II phase clinical study of asparaginase combined with etoposide, high-dose methotrexate and PD-1 monoclonal antibody in patients with advanced NK/T cell lymphomas
Start Date01 Oct 2021 |
Sponsor / Collaborator- |
Pharmacokinetics and relative bioavailability of single intramuscular injection of asparaginase injection and Oncaspar in Chinese healthy adult male subjects (2)
Start Date05 May 2020 |
Sponsor / Collaborator- |
International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is most effective for treating infants with acute lymphoblastic leukemia.
PURPOSE: Randomized phase III trial to compare the effectiveness of different combination chemotherapy regimens in treating infants who have newly diagnosed acute lymphoblastic leukemia.
Start Date01 May 1999 |
Sponsor / Collaborator- |
100 Clinical Results associated with Asparaginase (Pharmedic Laboratories Pvt Ltd.)
100 Translational Medicine associated with Asparaginase (Pharmedic Laboratories Pvt Ltd.)
100 Patents (Medical) associated with Asparaginase (Pharmedic Laboratories Pvt Ltd.)
100 Deals associated with Asparaginase (Pharmedic Laboratories Pvt Ltd.)